Press Releases Jun 03, 2024 Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 20, 2024 Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China May 08, 2024 Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress View all press releases Presentations & Events View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
May 20, 2024 Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
May 08, 2024 Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress